At NeoGenomics, we’re excited to announce the launch of our new National Mobile Phlebotomy Service for our blood-based tests. This service addresses the challenges and impact of COVID-19 for oncology patients requiring timely testing to ensure efficient diagnosis and disease progression monitoring.
Tests offered include InVisionFirst®-Lung, advanced non-small cell lung cancer liquid biopsy test, and the NeoLAB® liquid biopsy suite of tests encompassing solid tumor and hematologic cancers.
Listen to Douglas VanOort, NeoGenomics’ Chairman and Chief Executive Officer, as he describes the impact of COVID-19 on cancer patients across the US; and why it is so important that this in-home service addresses patient fears of exposure to COVID-19 to ensure the efficient continuity of care so crucial in the treatment and monitoring of cancer patients.
NeoGenomics will offer in-home mobile phlebotomy services through two phlebotomy companies for broad national geographic coverage to ensure tests are performed conveniently and quickly for fast results. NeoGenomics will arrange for the blood sample collection at the patient’s desired location and cover the expense of the mobile phlebotomy blood service.
For more information about NeoGenomics’ National Mobile Phlebotomy Service, please contact NeoGenomics’ Client Services at 1-866-776-5907.
http://phlebotomycareertraining.org/launching-neogenomics-new-national-mobile-phlebotomy-service-for-blood-based-oncology-tests/
No comments:
Post a Comment